To the full analysis
Haisco Pharmaceutical Group stock: valuation and P/E
002653.SZHaisco Pharmaceutical Group trades at a P/E of 49.4 (Biotechnology median 45.8, own median of recent years 48.3).
Daily figure as of 13 Nov 2026
P/E
49.4
P/S
11.1
P/B
11.11
PEG
no data
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
49.4
Median of prior years
48.3
Reading
in its usual range
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2016 | 38.1 |
| 2017 | 48.3 |
| 2018 | 36.7 |
| 2019 | 44.3 |
| 2020 | 29.2 |
| 2021 | 63.7 |
| 2022 | 85.6 |
| 2023 | 85.7 |
| 2024 | 95 |
| 2025 | 223.1 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.